Expertise in
9
conditions

Dr. Walid I. El Ayass

Hematology
Office
11105 Cathage Rd, 
Berlin, MD 
Accepting New Patients
Offers Telehealth
Expertise in
9
conditions
Office
11105 Cathage Rd, 
Berlin, MD 

Overview

Walid El Ayass is a Hematologist practicing medicine in Berlin, Maryland.

Dr. El Ayass is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Thrombocytopenia, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 5 clinical trials. Dr. El Ayass is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MD

Hospital Affiliations

Tidalhealth Peninsula Regional, Inc
Tidalhealth Nanticoke, Inc.
Luminis Health Anne Arundel Medical Center, Inc

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Office
11105 Cathage Rd, Berlin, MD 21811
Other Locations
TidalHealth Peninsula Regional
100 E Carroll St, Salisbury, MD 21801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 4 Less Clinical Trials

3 Total Publications

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 10, 2026
Similar Doctors
Expertise in
60
conditions
Dr. Rabindra Paul
Hematology | Oncology
Expertise in
60
conditions
Dr. Rabindra Paul
Hematology | Oncology
Referral may be required

Atlantic General Hospital Corp.

9707 Healthway Dr, 
Berlin, MD 
 (3.8 miles away)
410-629-6888
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rabindra Paul is a Hematologist and an Oncologist practicing medicine in Berlin, Maryland. Dr. Paul is highly rated in 60 conditions, according to our data. His clinical expertise encompasses Inflammatory Breast Cancer, Colorectal Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Paul is currently accepting new patients.

Expertise in
62
conditions
Dr. Justin Kucinski
Hematology | Oncology
Expertise in
62
conditions
Dr. Justin Kucinski
Hematology | Oncology
Referral may be required

Peninsula Regional Oncology & Hematology Ocean Pines

11105 Cathage Rd, 
Berlin, MD 
 (0.1 miles away)
410-912-4934
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Kucinski is a primary care provider, a Hematologist and an Oncologist in Berlin, Maryland. Dr. Kucinski is highly rated in 62 conditions, according to our data. His clinical expertise encompasses Dehydration, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Iron Deficiency Anemia, and Bone Marrow Aspiration. Dr. Kucinski is currently accepting new patients.

Expertise in
43
conditions
Expertise in
43
conditions
Referral may be required

Tunnell Cancer Center

18947 John J Williams Hwy Unit 101, 
Rehoboth Beach, DE 
 (21.4 miles away)
302-645-3770
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Nisarg Desai is a Hematologist practicing medicine in Rehoboth Beach, Delaware. Dr. Desai is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Essential Thrombocythemia, Thrombocytopenia, Adult Immune Thrombocytopenia, and Hemangioma Thrombocytopenia Syndrome. Dr. Desai is currently accepting new patients.

Frequently Asked Questions about Dr. Walid I. El Ayass

How do I make an appointment with Dr. Walid I. El Ayass?

You can book an appointment with Dr. Walid I. El Ayass by calling their office at 410-912-4934. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Walid I. El Ayass a top-rated expert for Chronic B-Cell Leukemia (CBCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Walid I. El Ayass is classified as an Advanced expert for Chronic B-Cell Leukemia (CBCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Walid I. El Ayass specialize in?

While Dr. Walid I. El Ayass is a Hematology, they have specific expertise in Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Walid I. El Ayass participate in research or clinical trials?

Yes. Dr. Walid I. El Ayass has published 3 articles and abstracts on conditions like Chronic B-Cell Leukemia (CBCL). You can view a list of Dr. Walid I. El Ayass's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Walid I. El Ayass accept my insurance?

Dr. Walid I. El Ayass accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 410-912-4934 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. El Ayass's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 47 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile